Researchers performed a cost analysis of the DRCR Retina Network’s Protocol AC study comparing on-label and off-label anti-VEGF use in DME therapy. What did they determine? Moderator Priya Vakharia, MD, invites panelists Sruthi Arepalli, MD, and Vaidehi Dedania, MD, to review the details of this economic examination. After the break, they explore how studies such as this one affect policy and probe the relevance of these findings in a world with longer-acting therapeutic agents.